



## Vaccine Stability Considerations to Enable Rapid Development and Deployment VIRTUAL WORKSHOP

### Wednesday, March 24, 2021

<b>10:30 am – 12:00 pm</b>	<b>Part 1</b>
10:30 am – 10:35 am	Introduction and Welcome (Jianmei D. Kochling, Ph.D., M.S., Sanofi) (Kim HuynhBa, M.S., PMP, FAAPS, Pharmalytik LLC)
10:35 am – 11:05 am	Session 1: Vaccine Formulation Challenges in a Pandemic Setting (Lisa Kuelczo, Ph.D., National Institutes of Health (NIH))
11:05 am – 11:55 am	Panel Discussion: Key Challenges to Find a Vaccine in a Global Pandemic (Lisa Kuelczo, Ph.D., National Institutes of Health (NIH)) (Michael Angelastro, Ph.D., BARDA) (Gayle Pulle, Ph.D., Health Canada) (Jianmei D. Kochling, Ph.D., M.S., Sanofi) (Kim HuynhBa, M.S., PMP, FAAPS, Pharmalytik LLC)
11:05 am – 11:30 am	Session 2: Key Considerations to Find a Vaccine in a Global Pandemic
11:30 am – 11:55 am	Panel Discussion (Dilip R. Choudhury, PhD, Independent Consultant) (Laure L. Larkin, MS, CPP, Johnson & Johnson) (Gillian French, PhD) (Kartik Narayan, PhD, Sanofi Pasteur) (Arjen Scholten, Ph.D., Janssen Vaccines and Prevention B.V.)
11:55 am – 12:00 pm	Closing Remarks
<b>2:00 pm – 4:00 pm</b>	<b>Part 2</b>
2:00 pm – 2:05 pm	Introduction and Welcome (Laure L. Larkin, MS, CPP, Johnson & Johnson) (Dilip R. Choudhury, Ph.D., Independent Consultant)
2:05 pm – 2:30 pm	Session 3: Covid-19 Vaccine EUA Stability Approach (Arjen Scholten, Ph.D., Janssen Vaccines and Prevention B.V.)

2:30 pm – 2:55 pm	Session 4: Coronavirus and Lessons from Annual Flu Programs
2:55 pm – 3:25 pm	Session 5: Analytical Characterization of a BEVS-derived Spike Protein Construct (Kartik Narayan, Ph.D., Sanofi)
3:25 pm – 3:50 pm	Panel Discussion (Dilip R. Choudhury, Ph.D., Independent Consultant) (Laure L. Larkin, MS, CPP, Johnson & Johnson) (Gillian French, PhD) (Arjen Scholten, Ph.D., Janssen Vaccines and Prevention B.V.) (Kartik Narayan, PhD, Sanofi Pasteur)
3:55 pm – 4:00 pm	Closing Remarks

#### Thursday, March 25, 2021

<b>10:30 am – 12:00 pm</b>	<b>Part 3</b>
10:30 am – 10:35 am	Introduction and Welcome (Lori McCaig, Ph.D., Seagen, Inc.) (Nanda Subbarao, Ph.D., Biologics Consulting)
10:35 am – 11:00 am	Session 6: Principles and Practices of Vaccine Stability Modeling (Tim Schofield, CMC Sciences)
11:00 am – 11:30 am	Session 7: Taking Stability off the Critical Path of Product Development (Andrew Lennard, Ph.D., Amgen)
11:30 am – 11:55 am	Panel Discussion (Lori McCaig, Ph.D., Seagen, Inc.) (Nanda Subbarao, PhD, Biologics Consulting Group, Inc.) (Tim Schofield, CMC Sciences) (Andrew C. Lennard, PhD, Amgen Inc.) (Stephanie Ferrari, MS, Pfizer) (Julia O'Neill, MS, Moderna Inc.)
11:55 am – 12:00 pm	Closing Remarks
<b>2:00 pm – 4:00 pm</b>	<b>Part 4</b>
2:00 pm – 2:05 pm	Introduction and Welcome (Yajie Zhang, Ph.D., Regeneron Pharmaceuticals) (Yan Wu, Ph.D., Merck)
2:05 pm – 2:30 pm	Session 8: Formulation and Distribution Impact on Immunology (Michael D. Swanson, Ph.D., Merck & Co Inc.)

2:30 pm – 2:55 pm	Session 9: Challenges of Vaccine Distribution and Deployment (Nada Sanders, Ph.D., Northeastern University)
2:55 pm – 3:25 pm	Session 10: The Last Mile: Ensuring Proper Storage and Handling at the Vaccination Center (Tony Reed, MD, PhD, MBA, CPE, Temple Health)
3:25 pm – 3:55 pm	Panel Discussion (Yajie Zhang, PhD, Regeneron Pharmaceuticals) (Yan Wu, PhD, Merck Sharp & Dohme) (Michael D. Swanson, PhD, Merck & Co Inc.) (Nada Sanders, PhD, Northeastern University (Tony S. Reed, MD, PhD, MBA, CPE, Temple University Health System)
3:55 pm – 4:00 pm	Closing Remarks